Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Effects of Initiating or Switching to a Six-Monthly Triptorelin Formulation on Prostate Cancer Patient–Healthcare Interactions and Hospital Resource Use: a Real-World, Retrospective, Non-Interventional Study

Abstract Introduction Luteinising hormone-releasing hormone agonist (LHRHa) injections are currently used in the treatment of advanced prostate cancer, but the frequency of injections may represent a burden to patients and healthcare services. The aim of this study was to collect real-world evidence...

Full description

Bibliographic Details
Main Authors: Philip Cornford, Kieran Jefferson, Owen Cole, John Gilbody
Format: Article
Language:English
Published: Adis, Springer Healthcare 2018-11-01
Series:Oncology and Therapy
Subjects:
Luteinising hormone-releasing hormone agonist
Prostate cancer
Prostate-specific antigen
Real-world evidence
Resource utilisation
Six-monthly triptorelin
Online Access:http://link.springer.com/article/10.1007/s40487-018-0087-1

Similar Items

Similar Items